Biopôle Lausanne’s Post

Who are Docpreneurs? MDs moving to entrepreneurship to address underserved needs in healthcare delivery. How to make this possible? Read below.

🌐Another partner presentation to kick-off the week 🚀 Biokeralty Research Institute, a dynamic R&D powerhouse within the Keralty Group, is at the forefront of groundbreaking research and development! 🧬💡 In alignment with Keralty’s Health Model, BioKeralty is dedicated to driving innovation across various health domains. Their primary focus areas include chronicity, regenerative medicine, cancer, personalized medicine, and digital health, among others. 💊🩺 🤝 As a consortium partner, BioKeralty is dedicated to managing intellectual property, disseminating results, and maximizing the impact across diverse stakeholder communities 🌍. Their committment extends to integrating knowledge management into project design, paving the way for future commercialization of therapeutic drugs. 💼 📢 Join us in celebrating BioKeralty's dedication to advancing health research and making a lasting impact of IN-ARMOR PROJECT EU 🌟 #HealthInnovation #ResearchandDevelopment #BioKeralty #KeraltyGroup #InnovationJourney #InArmorproject #horizoneurope #eucommission #antimicrobialresistance

We are thrilled to announce that AmiLyfe BioScience has acquired the assets of Entrinsic Bioscience, a strategic move that significantly enhances our capabilities and broadens our product portfolio. This acquisition includes rights to over 180 patents and trademarks, the renowned enterade® brand, and all existing licenses and product lines, establishing a robust technology platform fueled by our expertise in biomapping and electrophysiology. Key Highlights: Advanced Technology: With the integration of Entrinsic Bioscience’s assets, we now possess a powerful arsenal of IP and product lines, enhancing our innovative capabilities. Maestro™ AI Platform: Our proprietary AI platform, Maestro™, accelerates research into the cellular dynamics of natural amino acids, revealing their impact on crucial physiological functions. Expanded Product Line: We’ve identified over 50 biofunctional formulations targeting gut health, hydration, respiratory disease, and skincare, all clinically proven to provide significant health benefits. Innovative Solutions: Our flagship product, enterade oncology®, is a pioneering medical food that reduces the side effects of chemotherapy, radiation, and immunotherapy, benefiting patients in over 700 cancer centers worldwide. "AmiLyfe is here to revolutionize healthcare by blending biology and nature to elevate wellness from within." - Stephen Gatto, Chairman and CEO From protecting astronauts from GI effects during space travel to combating severe dehydration in infants and optimizing sports performance, our journey over the past 15 years has been marked by groundbreaking research and development. This acquisition propels us further in our mission to create scientifically validated, IP-protected products that improve the quality of life for individuals worldwide. Join us as we embark on this exciting new chapter, advancing health and wellness through the transformative power of natural amino acids! #HealthcareInnovation #AmiLyfeBioscience #Bioscience #HealthAndWellness #Sustainability #Innovation

👀 Did you miss the roundtable "Catalonia Advanced Therapies Ecosystem: Building Europe’s Future in ATMPs" at #RESIEurope2024? You can watch the recording of the debate here 👇 ▶️ https://lnkd.in/dYUZ8Cq5 The panel discussion highlighted the key role Catalonia’s advanced therapies will play in innovation and clinical breakthroughs in Europe. As Robert Fabregat Fuentes (#Biocat's CEO) emphasized: Catalonia ranks 5th in Europe and 8th worldwide in participation in clinical trials of #ATMPs. Moreover, the #BioRegion stands out in the number of publications on advanced therapies. 🗣 Luis Pareras MD, PhD (Invivo Partners) pointed to the quality of Catalan research: "In the field of advanced therapies and synthetic #biology, we have some of the best scientists in Europe and the world." For the roundtable participants, the main challenges posed by advanced therapies include attracting qualified #talent and ensuring patients' access to therapies. 🗣 Fina Lladós Canela (Amgen España) highlighted the need to scale up therapy production and ensure patient access: "It makes no sense to invest and attract innovation if it does not reach patients." Similarly, Esteve Trias i Adroher (Leitat Technological Center) expressed that while Catalonia is strong at both the beginning and end of the chain, it is fundamental to 💬 "build this bridge between research and transfer." 🗣 For Silvia Martín Lluesma (Vall d'Hebron Institute of Oncology (VHIO)), what is crucial is that researchers, clinicians, and regulatory professionals work hand in hand in the development of advanced therapies. To address these and other challenges in advanced therapies, Antoni Matilla Dueñas (BIOINTAXIS) brought up the recent creation of the Advanced Therapies Network of Catalonia, coordinated by #Biocat. 👉 This network aims to promote #research, manufacturing, and development of #AdvancedTherapies to make them accessible to the public efficiently and sustainably. #RESIEUROPE #RESIBARCELONA #RESI #ATMPs #AdvancedTherapies Life Science Nation

The Weekly BHI E-Newsletter is live: 📈 TEDCO Invests in Linshom Medical, Inc.: Maryland's support for improved patient safety continues with a $400K investment in Linshom's innovative wearable sensor technology. Learn more about this vital investment here. 🧠 Gain Therapeutics: Phase 1 Clinical Trial Initiation: Gain Therapeutics kicks off the Multiple Ascending Dose (MAD) phase of its Phase 1 trial for GT-02287, a novel therapy targeting GBA1 Parkinson’s disease. Dive into the details of this promising development. 💡 ATCC and Tissue Dynamics Collaborate for Heart Health: A strategic partnership between ATCC and Tissue Dynamics aims to revolutionize cardiac safety testing with advanced cardiac organoid-based kits. Discover more about this groundbreaking collaboration. 👩🔬 BioBuzz's 10 Women Shaping the Life Sciences: In celebration of Women’s History Month, BioBuzz highlights 10 remarkable women making significant contributions to the BioHealth Capital Region's life sciences sector. 🚀 Rockville Economic Development, Inc. (REDI) BioBoost Series: REDI launches its inaugural BioBoost event, "The Future of Bio/Life Science Funding in 2024," offering industry professionals valuable insights into the latest investment trends and funding opportunities. 💊 The March-In Debate: Three Congressional Letters Signal Shift: Delve into the evolving discussion surrounding the Biden Administration's proposed march-in guidelines and their potential impact on American innovation. 🏢 Cartesian Therapeutics' New Headquarters: Cartesian Therapeutics relocates its corporate headquarters to Frederick, Maryland, unveiling a cutting-edge mRNA cell therapy manufacturing facility. Learn more about this milestone move. Visit the link to read all these stories and more. https://lnkd.in/ewY_hzfh

All investors in the panel “Biotech Funding: Navigating Challenges, Exploring Solutions” at #KnowledgeforGrowth today agreed that the craziness on the biotech capital market might be over, but that this is actual a good thing because the focus is again on substance, on matter not on hype. Christina Takke, Katrien Swerts, Jan Van den Bossche, Richard Reschen, Servaas Michielssens, PhD, CFA were the panelists and Bram Van Parys was the moderator of this session. Companies with good data will get good funding, according to the investors. And if a company can reach milestones without spending too much money, even better. This shows that the company is well organized and can manage its projects well. In Europe companies need to work on shoestring budgets more often, compared to the US, but they are also usually better at it. This is a good thing because most investors want efficient use of cash according to the speakers. And pressure on the budget often also results in smart, creative solutions. The next big think the panelists are keeping a close eye on are the technical fields of obesity, metabolism, siRNA’s, especially in neurobiology in the field of Alzheimer’s and ALS. Further, new biomarkers allow more effective clinical testing, which already resulted for example in the recent amyloid approvals. Precision fermentation, cell free fermentation with increased carbon utilization as an advantage, and capturing CO2, and growing bacteria on CO2 only are also promising fields, as are therapies in oncology brought to other fields such as immunology, as well as AI in health tech and drug development, which is expected to increase speed, reduce costs, and result in better products.

🚀 Exciting Collaboration & preparation of out-licensing: Xlife Sciences AG & Quant Biomarkers AG We're excited to announce a groundbreaking collaboration between Xlife Sciences AG and Quant Biomarkers AG, a strategic move that not only advances CKD diagnosis but also paves the way for our next successful out-licensing venture. 🔬 Revolutionizing CKD Detection - This partnership focuses on developing innovative biomarkers for early detection of chronic kidney disease (CKD), a condition affecting 13.4% of the global population. Our collaboration is set to transform the approach to CKD diagnosis, offering hope for earlier and more effective treatment. 💡 Vision for the Future - Our goal is to change the landscape of CKD treatment, allowing for early intervention and potentially preventing irreversible kidney damage. 🚀 A Step Towards Transformative Healthcare - Join us on this exciting journey as we redefine kidney health and set new standards in the life sciences sector. https://lnkd.in/edB8HMnd

We’re honored that Alcami and our CEO William Humphries were included in Investment Reports' new publication, 'The New Era of Life Sciences 2024'. Don’t miss this comprehensive and inspiring exploration of the advancements shaping healthcare and beyond. Download it here: https://lnkd.in/efABSXnm #Alcami #CEO #InvestmentReports #LifeSciences

We’re honored that Alcami and our CEO William Humphries were included in Investment Reports' new publication, 'The New Era of Life Sciences 2024'. Don’t miss this comprehensive and inspiring exploration of the advancements shaping healthcare and beyond. Download it here: https://lnkd.in/eSkStUF9 #Alcami #CEO #InvestmentReports #LifeSciences

📢 Attention Oncology Researchers! Looking to accelerate your research and elevate your oncology insights? Sign up for the beta testing program of the Human Tumor Biomarker Performance Luminex Panel from Bio-Techne. This customizable panel includes up to 28 tumor biomarkers and is designed to work with your Luminex instrument. Find the link below: https://lnkd.in/duJunGuX Don't miss out on this great opportunity to enhance your research capabilities. Sign up now by clicking on the link below. #oncologyresearch #biomarkerpanel #betatesting #LuminexAssays #BioTechne